An inhaled antibiotic from Insmed (INSM) successfully treated patients with a rare lung disease caused by a bacterial infection, according to results from a phase 3 clinical trial reported Tuesday.

Based on the findings from the phase 3 study, Insmed said it plans to seek accelerated approval from the FDA for the inhaled antibiotic, known as ALIS, as a new treatment for adults with nontuberculous mycobacterial (NTM) lung disease.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have Interstatial Pulmonary Fibrosis exhibiting by lots of scaring which is random in its presentation. Would this medication allow my O2 intake to pass more easily into my blood stream ??

    • William, I am not an MD, but I can tell you that the late Jerry Lewis had interstitial pulmonary fibrosis, for which he received high dose steroids. It’s a tough treatment but was helpful in his case.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy